Physician profile
Jason E Quicho
NPI 1518312156
$3,354.38
in general payments reported to CMS, 2019-2025
13 companies · $824 in 2025
The $824 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $772 · 2023: $844 · 2024: $915 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,582.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.36 | 2022-2024 | |
| Incyte Corporation | $376.17 | 2022-2023 | Opzelura |
| Lilly USA, LLC | $360.19 | 2022-2024 | Taltz, Olumiant |
| Dermavant Sciences, INC. | $339.03 | 2023-2024 | Vtama |
| Genzyme Corporation | $316.19 | 2023-2025 | |
| Galderma Laboratories, L.P. | $271.72 | 2025 | Nemluvio |
| Organon LLC | $167.86 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $134.38 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $132.83 | 2025 | Zoryve |
| Viiv Healthcare Company | $122.39 | 2025 | Apretude |
| Leo Pharma INC. | $107.09 | 2022 | |
| Pfizer INC. | $99.98 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $87.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Quicho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.